{"gene":"ERG","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":1987,"finding":"ERG was identified as a member of the ETS oncogene family, encoding a 363-residue protein with approximately 40% and 70% homology to two domains of v-ets oncogene, establishing its identity as a distinct ETS transcription factor.","method":"cDNA cloning and nucleotide sequence analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — original cloning and sequence characterization, foundational paper","pmids":["3476934"],"is_preprint":false},{"year":1994,"finding":"ERG gene is translocated in Ewing's sarcoma via a chromosomal rearrangement juxtaposing the 5' end of EWS to the 3' end of ERG, generating an EWS/ERG fusion transcript expressed at elevated levels.","method":"RT-PCR, cytogenetic and molecular analysis of Ewing's sarcoma cell line","journal":"Cancer genetics and cytogenetics","confidence":"High","confidence_rationale":"Tier 1 — direct sequencing and transcript detection of fusion gene in cancer cell line","pmids":["8076344"],"is_preprint":false},{"year":1995,"finding":"Overexpression of ERG2 in NIH3T3 cells confers oncogenic transformation, including growth in low serum, colony formation in soft agar, and tumor formation in nude mice, establishing ERG as a proto-oncogene with mitogenic and transforming activity.","method":"Stable transfection of ERG2 expression construct into NIH3T3 cells; soft agar colony assay; nude mouse xenograft","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro and in vivo transformation assays with multiple orthogonal readouts","pmids":["7731694"],"is_preprint":false},{"year":2001,"finding":"ERG isoforms (Erg-3/p55(Erg) and p38(Erg)) are selectively expressed in endothelial cells among human cell types, indicating isoform-specific roles in regulation of endothelial-restricted gene expression.","method":"RT-PCR, Northern blotting, 5'-RACE on primary and established human cell lines","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple molecular methods, single lab","pmids":["11312105"],"is_preprint":false},{"year":2001,"finding":"ERG physically interacts with Jun/Fos heterodimer through its ETS DNA-binding domain; residue R367 is required for both DNA binding and Erg-Jun/Fos complex formation, while Y371 is specifically required for transcriptional synergy with Jun/Fos without abolishing DNA binding.","method":"Deletion and point mutagenesis of ERG ETS domain; in vitro binding and transcriptional activation assays; molecular modeling","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution, mutagenesis, and functional assays in a single study","pmids":["11278640"],"is_preprint":false},{"year":2002,"finding":"ERG1 K+ channel is constitutively tyrosine-phosphorylated and forms a signaling complex with Src tyrosine kinase; Src activation increases ERG current amplitude and shifts voltage dependence, while Src inhibition reduces ERG current.","method":"Co-immunoprecipitation; whole-cell patch clamp; Src-selective inhibitory/activating peptides; constitutively active v-Src transfection","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — co-IP plus electrophysiology plus mutagenesis/peptide tools, multiple methods","pmids":["11834728"],"is_preprint":false},{"year":2003,"finding":"In Ewing's tumors lacking EWS rearrangement, FUS is fused in-frame to ERG, placing the FUS transactivation domain adjacent to the ERG ETS DNA-binding domain, demonstrating interchangeability of TET family transactivation domains with ETS factors in oncogenesis.","method":"Sequence-level RT-PCR fusion transcript characterization; BAC FISH on metaphase and interphase nuclei","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 — direct sequencing of fusion junctions plus FISH validation","pmids":["12907633"],"is_preprint":false},{"year":2004,"finding":"Muscarinic receptor stimulation inhibits ERG1 K+ current through a Gq/11-dependent pathway requiring a minimum intracellular Ca2+ level but not a Ca2+ transient, protein kinase C, or tyrosine kinases; recovery is partially dependent on PIP2 resynthesis.","method":"Whole-cell patch clamp; co-expression with M1 muscarinic receptors; dominant-negative Gq; constitutively active G-protein constructs; BAPTA Ca2+ chelation; pharmacological inhibitors","journal":"The Journal of physiology","confidence":"High","confidence_rationale":"Tier 1 — reconstitution in defined expression system with multiple orthogonal pharmacological and molecular tools","pmids":["15235086"],"is_preprint":false},{"year":2005,"finding":"ERG is expressed in hematopoietic stem cells and megakaryoblastic cells; forced ERG expression in K562 erythroleukemia cells induces an erythroid-to-megakaryoblastic phenotypic switch; ERG activates the gpIb megakaryocytic promoter and binds the gpIIb promoter and the SCL/TAL1 hematopoietic enhancer in vivo.","method":"Cell line forced expression; megakaryocytic differentiation assays; in vivo ChIP; promoter reporter assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP, promoter reporter, and functional differentiation assays in multiple cell systems","pmids":["16140924"],"is_preprint":false},{"year":2008,"finding":"ERG is required for endothelial tube formation and cell survival; Erg inhibition reduces VE-cadherin expression; Erg binds directly to the VE-cadherin promoter (by ChIP) and transactivates it; overexpression of VE-cadherin partially rescues apoptosis caused by Erg inhibition; Erg knockdown in a Matrigel plug model decreases vascularization in vivo.","method":"Antisense oligonucleotides/siRNA knockdown; ChIP; transactivation assay; VE-cadherin-GFP rescue; in vivo Matrigel plug model","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP + reporter assay + functional rescue + in vivo validation, multiple orthogonal methods","pmids":["18195090"],"is_preprint":false},{"year":2008,"finding":"Overexpression of ERG in luminal prostate epithelial cells is sufficient to initiate prostate neoplasia (focal PIN) in transgenic mice; ERG overexpression in prostate cell lines increases cell invasion, and ERG protein is expressed in neoplastic human prostate epithelium.","method":"Transgenic mouse model with luminal-targeted ERG expression; invasion assays in prostate cell lines; ERG protein detection by Western/IHC","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic model plus in vitro invasion assays","pmids":["18245377"],"is_preprint":false},{"year":2008,"finding":"In zebrafish, erg functions downstream of cloche, tal1/scl, and etsrp in the angioblast specification pathway, and plays a redundant but specific role in angioblast specification/proliferation and early angiogenesis, with synergistic interaction with etsrp.","method":"Zebrafish morpholino knockdown; gain-of-function injection; in situ hybridization; epistasis analysis with cloche and other pathway genes","journal":"Mechanisms of development","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with multiple pathway components in vivo","pmids":["19027849"],"is_preprint":false},{"year":2009,"finding":"Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome (Ts65Dn); functional reduction of Erg to disomy corrects megakaryocytosis and progenitor cell expansion, establishing Erg gene dosage as a key driver of myeloproliferative phenotypes.","method":"Loss-of-function allele introduced into trisomic mouse model; hematologic and histopathologic phenotyping","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function in disease-relevant in vivo model with clear phenotypic readout","pmids":["20007548"],"is_preprint":false},{"year":2009,"finding":"ETS2, ERG, and FLI-1 overexpression promotes megakaryocyte expansion and, when combined with Gata1 mutations (knockdown or Gata1s knockin), immortalizes hematopoietic progenitors with JAK/STAT pathway activation.","method":"Retroviral overexpression in murine fetal liver progenitors; serial replating assays; flow cytometry; JAK/STAT pathway analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — defined genetic combinations with clear functional readouts (immortalization, differentiation block)","pmids":["19168790"],"is_preprint":false},{"year":2010,"finding":"ERG transcription factor binds directly to the CXCR4 gene promoter and drives androgen-dependent CXCR4 expression in TMPRSS2-ERG fusion-positive prostate cancer cells; ERG knockdown abolishes androgen-induced CXCR4 upregulation and functional CXCR4 signaling.","method":"ChIP demonstrating ERG binding to CXCR4 promoter; siRNA-mediated ERG knockdown; androgen stimulation assays; CXCR4 functional assays","journal":"Translational oncology","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP plus loss-of-function with functional downstream readout","pmids":["20563261"],"is_preprint":false},{"year":2011,"finding":"Forced ERG expression in adult bone marrow cells alters differentiation and promotes T-ALL development (with acquisition of Notch1 mutations) and B cell precursor growth in mouse transplantation models; shRNA-mediated silencing of ERG attenuates growth of human leukemia cell lines, establishing ERG as required for leukemia maintenance.","method":"Mouse BM transplantation with ERG-overexpressing cells; shRNA knockdown in human leukemia lines; flow cytometric lineage analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic model plus loss-of-function in human lines, multiple lineages tested","pmids":["21321361"],"is_preprint":false},{"year":2011,"finding":"ERG overexpression in prostate cells induces PIM1 upregulation; ERG directly binds the PIM1 promoter (by ChIP) in RWPE-1 prostate cells; PIM1 upregulation by ERG increases aneuploidy after taxane treatment and alters Cyclin B1 levels.","method":"ChIP of ERG at PIM1 promoter; siRNA-mediated ERG silencing; gene expression profiling; flow cytometry for aneuploidy","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP plus loss-of-function, single lab","pmids":["22140532"],"is_preprint":false},{"year":2013,"finding":"ERG regulates SOX9 expression indirectly by opening a cryptic androgen receptor (AR)-regulated enhancer in the SOX9 gene; ERG redirects AR to non-canonical targets including SOX9, which is a critical downstream effector of ERG-mediated invasion and tumor growth in TMPRSS2-ERG fusion-positive prostate cancer.","method":"RNAi knockdown of ERG in VCaP cells; ChIP-seq for AR and ERG; invasion assays; SOX9 knockdown in vivo and in vitro","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP-seq + loss-of-function + in vivo validation, multiple orthogonal methods","pmids":["23426182"],"is_preprint":false},{"year":2013,"finding":"miR-145 directly targets the 3' UTR of ERG mRNA; ectopic miR-145 expression reduces ERG protein levels in prostate cancer cells.","method":"3' UTR reporter assay; ectopic miR-145 expression with Western blot for ERG protein","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 — luciferase reporter and protein reduction, single lab","pmids":["23480797"],"is_preprint":false},{"year":2013,"finding":"ERG governs loss of DNA methylation at the TDRD1 promoter CpG island, leading to TDRD1 transcriptional activation; ERG dosage manipulation by siRNA and forced expression directly controls TDRD1 promoter methylation status in prostate cancer cells.","method":"MeDIP-seq; bisulfite sequencing; ERG siRNA knockdown and forced expression; DNMT inhibitor treatment","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — genome-wide methylation profiling plus gain/loss of function, single lab","pmids":["23555854"],"is_preprint":false},{"year":2015,"finding":"SPOP, a Cullin 3-based E3 ubiquitin ligase substrate adaptor, promotes ubiquitination and proteasomal degradation of wild-type ERG by recognizing a degron motif at the ERG N-terminus; prostate cancer-associated SPOP mutants are deficient in ERG ubiquitination; CKI-mediated phosphorylation of ERG modulates SPOP-ERG interaction; DNA damage drugs (topoisomerase inhibitors) restore the SPOP/ΔERG interaction to promote ΔERG degradation.","method":"In vitro ubiquitination assay; co-immunoprecipitation; mutagenesis of ERG degron; proteasome inhibitor assays; pharmacological drug treatment","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro ubiquitination plus co-IP, mutagenesis, and pharmacological validation","pmids":["26344095"],"is_preprint":false},{"year":2015,"finding":"N-terminally truncated ERG proteins encoded by TMPRSS2-ERG fusions lack the N-terminal SPOP degron motif and are resistant to SPOP-mediated proteasomal degradation; prostate cancer-associated SPOP mutations also abrogate ERG degradation.","method":"In vitro ubiquitination assay; co-immunoprecipitation; degron mutagenesis; proteasomal degradation assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — independent replication of SPOP-ERG ubiquitination mechanism with degron mapping","pmids":["26344096"],"is_preprint":false},{"year":2015,"finding":"ERG directly activates the YAP1 promoter through multiple ETS binding sites; ERG binds directly to KDM4A histone demethylase; ERG-KDM4A cooperation reduces H3K27me3 at the YAP1 promoter; YAP1 depletion phenocopies the growth-inhibitory effect of ERG depletion in VCaP prostate cancer cells.","method":"Co-IP; promoter reporter assay with ETS site mutagenesis; ChIP for H3K27me3; siRNA knockdown","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP plus ChIP plus reporter mutagenesis, single lab","pmids":["27109047"],"is_preprint":false},{"year":2015,"finding":"ERG conditional knockout in mouse joints leads to progressive osteoarthritis-like cartilage degeneration; ERG directly binds ETS sites in the PTHrP and lubricin gene promoters to stimulate their expression; ERG is required for maintenance of articular cartilage homeostasis postnatally.","method":"Conditional knockout (Gdf5-Cre x floxed Erg); surgical OA model; promoter-reporter assays with mutated ETS binding sites; gene expression analysis","journal":"Arthritis & rheumatology","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with disease phenotype plus mechanistic reporter assays","pmids":["26097038"],"is_preprint":false},{"year":2016,"finding":"TRIM25 E3 ubiquitin ligase binds and polyubiquitinates full-length and N-terminally truncated ERG variants in vitro; TRIM25 inactivation reduces ERG polyubiquitination and stabilizes ERG protein; ERG upregulates TRIM25 expression, creating a regulatory feedback loop; USP9X deubiquitinase counteracts TRIM25 to stabilize ERG.","method":"Co-immunoprecipitation; in vitro ubiquitination assay; TRIM25 knockdown with ERG stability measurement","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution of ubiquitination plus co-IP and loss-of-function","pmids":["27626314"],"is_preprint":false},{"year":2016,"finding":"VEGF/ERK signaling induces phosphorylation and activation of ERG in endothelial cells; phospho-ERG recruits the co-activator p300 to drive transcription of DLL4 and a network of VEGF-responsive target genes; ERG ChIP-seq identifies conserved ERG-bound enhancer elements near these target genes including HLX.","method":"ERK inhibition; ERG phosphorylation assays; ChIP for ERG and p300; genome-wide gene expression; ChIP-seq; genome editing of ERG-bound HLX enhancer","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP-seq plus enhancer editing plus in vivo validation, multiple methods","pmids":["28536097"],"is_preprint":false},{"year":2016,"finding":"The TMPRSS2-ERG encoded truncated ERG (ERGΔ39/T1-E4) binds to bromodomain-1 (BD1) of BRD4; ERG and BRD4 co-occupy a substantial portion of genomic sites; an acetylation-mimicking mutation in ERG enhances the ERG-BRD4 interaction and augments ERG-mediated cell invasion; BET inhibitors partially abrogate this interaction.","method":"Co-IP; ChIP-seq meta-analysis; acetylation-mimicking ERG mutant; BET inhibitor treatment; invasion assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-IP plus ChIP-seq overlap plus mutagenesis, single lab","pmids":["27223260"],"is_preprint":false},{"year":2016,"finding":"DUX4 rearrangement in B-ALL drives expression of a novel ERG isoform (ERGalt) via a non-canonical first exon initiated by DUX4 binding; ERGalt retains the DNA-binding and transactivation domains of ERG, functions as a dominant-negative inhibitor of wild-type ERG transcriptional activity, and is transforming.","method":"Genomic sequencing; transcriptional assays; dominant-negative functional assays; transformation assays","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1-2 — identification of DUX4 binding driving ERGalt expression plus functional dominant-negative and transformation assays","pmids":["27776115"],"is_preprint":false},{"year":2017,"finding":"FOXO1 binds directly to ERG and inhibits its transcriptional activity independently of FOXO1's own transcriptional activity; FOXO1 knockdown increases invasion in TMPRSS2-ERG fusion-positive cells in an ERG-dependent manner; combined ERG transgene expression and Foxo1 deletion in mouse prostate produces high-grade PIN, whereas either alone does not.","method":"Co-IP of FOXO1 and ERG; FOXO1 knockdown + ERG knockdown epistasis; transgenic mouse model; in vitro invasion assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — co-IP plus epistatic genetic model plus in vitro functional assays","pmids":["28986382"],"is_preprint":false},{"year":2018,"finding":"ERG interacts with the mammalian SWI/SNF (BAF) chromatin remodeling complex; ERG drives genome-wide retargeting of BAF complexes in an ETS DNA motif-dependent manner; ERG requires intact BAF complexes for chromatin occupancy and BAF ATPase activity for target gene regulation; BAF complexes are required for ERG-mediated basal-to-luminal transition in prostate organoids.","method":"Co-IP/pulldown; ChIP-seq of ERG and BAF subunits; BAF ATPase inhibition; prostate organoid model with BAF depletion","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 — co-IP + genome-wide ChIP-seq + ATPase inhibition + organoid functional assay, multiple orthogonal methods","pmids":["30078722"],"is_preprint":false},{"year":2018,"finding":"ERG directly binds and activates the FZD8 (Frizzled-8) gene promoter in prostate cancer cells; this activation is specific to ERG and not to the related ETS factor ETV1; ERG overexpression induces FZD8 expression, potentially activating Wnt signaling.","method":"ChIP demonstrating ERG binding at FZD8 promoter; promoter reporter assay; ERG knockdown; specificity comparison with ETV1","journal":"The Prostate","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP plus reporter assay, single lab","pmids":["30051493"],"is_preprint":false},{"year":2020,"finding":"ERG is essential for early B lymphoid differentiation; ERG initiates a transcriptional network involving EBF1 and PAX5 that promotes expression of V(D)J recombination genes and B cell receptor formation; complementation of Erg deficiency with a rearranged immunoglobulin gene rescues B lineage development.","method":"Conditional Erg knockout; RNA-seq/ChIP-seq; rescue with productively rearranged Ig gene; flow cytometric developmental analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with genetic rescue plus genome-wide transcriptional network mapping","pmids":["32541654"],"is_preprint":false},{"year":2020,"finding":"ERG inhibits a distal enhancer of Trp63 (a master regulator of prostate basal lineage) by binding it and reducing its chromatin looping activity, thereby silencing Trp63 and promoting luminal differentiation; specific deletion of the ERG-bound Trp63 enhancer removes ERG-mediated inhibition of basal differentiation.","method":"3D chromatin architecture analysis (Hi-C/ChIA-PET); ChIP-seq; ERG KO; AR KO comparison; targeted enhancer deletion","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 — 3D chromatin mapping plus targeted enhancer editing plus genetic KOs","pmids":["32701507"],"is_preprint":false},{"year":2021,"finding":"ERG upregulates wild-type SPOP to dampen androgen receptor (AR) signaling and sustains its own activity through SPOP-mediated degradation of the bromodomain histone reader ZMYND11; conversely, SPOP-mutant tumors stabilize ZMYND11 to repress ERG function, establishing opposing ERG-SPOP regulatory axes.","method":"Proteomics; ChIP-seq; co-IP; genetic manipulation of SPOP and ERG in organoid and mouse models; pharmacological SPOP inhibition","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including proteomics, ChIP-seq, genetic models","pmids":["33531470"],"is_preprint":false},{"year":2022,"finding":"ERG functions as a transcriptional orchestrator of lung capillary homeostasis; loss of endothelial ERG enhances paracrine fibroblast activation in vitro and impairs lung fibrosis resolution in vivo; ERG-deficient mouse lungs show reduced general capillary (gCap) endothelial cell numbers and transcriptional abnormalities resembling aging and human lung fibrosis.","method":"Epigenetic/transcriptional analysis (ATAC-seq, RNA-seq); conditional ERG deletion; scRNA-seq; in vitro co-culture fibroblast activation assay; bleomycin lung fibrosis model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with in vivo fibrosis phenotype plus in vitro functional assays and scRNA-seq","pmids":["35879310"],"is_preprint":false},{"year":2023,"finding":"EVI1 oncogene directly activates ERG transcription by occupying a conserved intragenic ERG enhancer; ERG is selectively required for EVI1-driven AML; ectopic ERG expression rescues AML cell dependence on EVI1, establishing ERG as the major oncogenic effector downstream of EVI1.","method":"CRISPR screens; ChIP-seq for EVI1 at ERG enhancer; ERG knockdown causing terminal differentiation; ERG rescue of EVI1-depleted cells; in vivo mouse models","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — CRISPR screens + ChIP-seq + genetic rescue, orthogonal mechanistic evidence","pmids":["36095844"],"is_preprint":false}],"current_model":"ERG is an ETS family transcription factor that binds DNA through its ETS domain and regulates target genes (including VE-cadherin, SOX9, CXCR4, PIM1, FZD8, YAP1, DLL4, PTHrP, EBF1, PAX5) directly or by redirecting cofactors such as AR, p300, KDM4A, and BAF chromatin remodeling complexes to enhancers; its protein stability is controlled by SPOP/Cullin3-mediated ubiquitination (dependent on an N-terminal degron) counterbalanced by USP9X deubiquitination, with TRIM25 as an additional E3 ligase; ERG is activated by VEGF/ERK-mediated phosphorylation in endothelial cells, modulated by Src tyrosine kinase and muscarinic/Gq signaling (in its role as the HERG K+ channel in cardiac/neuronal contexts), and is oncogenically activated in prostate cancer via TMPRSS2-ERG fusion (producing N-terminally truncated, SPOP-resistant isoforms), in leukemia via EWS/FUS fusions or EVI1-driven transcriptional upregulation, and in B-ALL via DUX4-driven expression of a dominant-negative ERGalt isoform."},"narrative":{"teleology":[{"year":1987,"claim":"Establishing ERG as a distinct ETS family member resolved its identity as a transcription factor with conserved DNA-binding and pointed domains, providing the foundation for all subsequent functional studies.","evidence":"cDNA cloning and sequence analysis revealing a 363-residue protein with ETS domain homology","pmids":["3476934"],"confidence":"High","gaps":["No target genes identified","No functional assay performed","Expression pattern unknown"]},{"year":1994,"claim":"Discovery of the EWS-ERG fusion in Ewing sarcoma established ERG as a recurrent translocation partner in human cancer, raising the question of whether ERG possesses intrinsic oncogenic activity.","evidence":"RT-PCR and cytogenetic analysis of Ewing sarcoma cell line identifying EWS-ERG fusion transcript","pmids":["8076344"],"confidence":"High","gaps":["Transforming activity of the fusion not directly tested","Mechanism of oncogenic activation unknown"]},{"year":1995,"claim":"Demonstrating that ERG overexpression alone transforms NIH3T3 cells confirmed ERG as a bona fide proto-oncogene, establishing that its oncogenic potential does not require a fusion partner.","evidence":"Stable ERG2 transfection with soft agar colony formation and nude mouse tumor growth","pmids":["7731694"],"confidence":"High","gaps":["Downstream transcriptional targets mediating transformation not identified","Relevance to human epithelial cancers not shown"]},{"year":2001,"claim":"Identification of endothelial-restricted ERG isoforms and mapping of the ETS domain's dual role in DNA binding and Jun/Fos interaction established ERG as a key endothelial transcription factor that integrates AP-1 signaling.","evidence":"RT-PCR/Northern blot profiling across human cell types; ETS domain mutagenesis with binding and transcriptional assays","pmids":["11312105","11278640"],"confidence":"High","gaps":["Endothelial target genes not identified","In vivo endothelial requirement not tested"]},{"year":2005,"claim":"Showing that ERG drives megakaryocytic differentiation and directly occupies hematopoietic gene promoters (gpIb, gpIIb, SCL enhancer) revealed its role as a lineage-instructive transcription factor in hematopoiesis.","evidence":"Forced expression in K562 cells with differentiation assays; in vivo ChIP at megakaryocytic promoters","pmids":["16140924"],"confidence":"High","gaps":["Loss-of-function in hematopoietic stem cells not performed","Functional redundancy with FLI-1 not resolved"]},{"year":2008,"claim":"Multiple studies converged to establish ERG as essential for endothelial tube formation, VE-cadherin-mediated survival, angioblast specification, and—when overexpressed in prostate—sufficient to initiate neoplasia, revealing its dual physiological and oncogenic roles.","evidence":"siRNA knockdown with ChIP/rescue for VE-cadherin in HUVECs; zebrafish morpholino epistasis; transgenic ERG-overexpressing mouse prostate model with invasion assays","pmids":["18195090","19027849","18245377"],"confidence":"High","gaps":["Endothelial ERG target gene network not mapped genome-wide","Cooperating oncogenic events for prostate cancer progression not defined"]},{"year":2009,"claim":"Genetic dosage experiments in trisomic mice demonstrated that Erg trisomy is required for myeloproliferation in Down syndrome, establishing ERG gene dosage as a driver of megakaryocyte expansion and linking it to human disease.","evidence":"Reduction of Erg to disomy in Ts65Dn mice correcting megakaryocytosis and progenitor expansion","pmids":["20007548"],"confidence":"High","gaps":["Direct transcriptional targets mediating megakaryocyte expansion not identified","Cooperation with GATA1 mutations in transient myeloproliferative disease not fully dissected"]},{"year":2013,"claim":"ChIP-seq in TMPRSS2-ERG fusion-positive prostate cancer cells revealed that ERG redirects androgen receptor to non-canonical enhancers including a cryptic SOX9 enhancer, establishing the mechanistic basis for ERG's oncogenic transcriptional reprogramming.","evidence":"Integrated ERG/AR ChIP-seq in VCaP cells; SOX9 knockdown phenocopying ERG loss in invasion and tumor growth","pmids":["23426182"],"confidence":"High","gaps":["Structural basis of ERG-AR interaction unknown","Whether AR redirection is sufficient without additional cofactors not tested"]},{"year":2015,"claim":"Two independent groups simultaneously discovered that SPOP/Cullin3 ubiquitinates ERG via an N-terminal degron that is absent in TMPRSS2-ERG fusion products, explaining why fusion-derived ERG escapes proteasomal degradation in prostate cancer.","evidence":"In vitro ubiquitination reconstitution; degron mutagenesis; proteasomal degradation assays with SPOP wild-type and cancer mutants","pmids":["26344095","26344096"],"confidence":"High","gaps":["In vivo therapeutic restoration of ERG degradation not demonstrated","Quantitative contribution of SPOP versus TRIM25 pathways unclear"]},{"year":2015,"claim":"Conditional ERG knockout in mouse joints revealed a physiological requirement for ERG in articular cartilage homeostasis through direct transcriptional activation of PTHrP and lubricin, extending ERG's known roles beyond endothelium and blood.","evidence":"Gdf5-Cre conditional knockout with progressive osteoarthritis phenotype; promoter-reporter assays with ETS site mutations","pmids":["26097038"],"confidence":"High","gaps":["Whether ERG loss contributes to human osteoarthritis not established","Upstream signals regulating ERG in chondrocytes unknown"]},{"year":2016,"claim":"Identification of TRIM25 as an additional E3 ligase for ERG and USP9X as a counteracting deubiquitinase, together with the discovery that ERG upregulates TRIM25 to create a feedback loop, revealed a multi-layered ubiquitin-dependent control circuit governing ERG protein levels.","evidence":"In vitro ubiquitination with TRIM25; co-IP of USP9X-ERG; TRIM25 knockdown stabilizing ERG protein","pmids":["27626314"],"confidence":"High","gaps":["Relative quantitative contribution of TRIM25 versus SPOP in different cell types not determined","Structural basis of USP9X recognition of ERG unknown"]},{"year":2016,"claim":"VEGF/ERK-dependent phosphorylation of ERG was shown to recruit p300 to drive DLL4 and angiogenic target gene transcription, while DUX4-driven ERGalt in B-ALL was identified as a dominant-negative isoform, demonstrating how post-translational and isoform-level mechanisms diversify ERG function.","evidence":"ERK inhibition with ERG phosphorylation and p300 ChIP assays; ChIP-seq enhancer mapping in endothelial cells; genomic sequencing and functional assays for DUX4-driven ERGalt","pmids":["28536097","27776115"],"confidence":"High","gaps":["Identity of kinase(s) phosphorylating specific ERG residues in endothelial cells not fully mapped","Structural basis of ERGalt dominant-negative activity not resolved"]},{"year":2018,"claim":"Demonstration that ERG physically recruits and retargets BAF chromatin remodeling complexes genome-wide, and that BAF ATPase activity is required for ERG's transcriptional output, established BAF as the principal chromatin effector of ERG-driven gene regulation.","evidence":"Co-IP/pulldown; genome-wide ChIP-seq of ERG and BAF subunits; BAF ATPase inhibition; prostate organoid basal-to-luminal transition assay","pmids":["30078722"],"confidence":"High","gaps":["Whether specific BAF subunit composition dictates ERG-dependent enhancer selection unknown","Whether BAF dependence applies to ERG functions in endothelial cells not tested"]},{"year":2020,"claim":"ERG was shown to be essential for early B lymphopoiesis by initiating a transcription factor cascade (EBF1, PAX5) required for V(D)J recombination, and separately to silence the basal lineage determinant Trp63 through three-dimensional chromatin loop disruption, revealing ERG as a master regulator of lineage fate in multiple tissues.","evidence":"Conditional Erg KO with RNA-seq/ChIP-seq and Ig gene rescue in B cells; Hi-C/ChIA-PET plus targeted enhancer deletion for Trp63 in prostate","pmids":["32541654","32701507"],"confidence":"High","gaps":["Whether ERG's 3D chromatin remodeling role extends to hematopoietic loci not examined","Redundancy with other ETS factors in B cell development not fully resolved"]},{"year":2022,"claim":"Conditional endothelial ERG deletion in adult mouse lungs impaired capillary homeostasis and fibrosis resolution, with transcriptional signatures resembling human lung fibrosis and aging, extending ERG's essential endothelial role from development to adult tissue maintenance.","evidence":"Conditional ERG deletion; scRNA-seq showing gCap loss; ATAC-seq/RNA-seq; bleomycin fibrosis model; in vitro paracrine fibroblast activation assay","pmids":["35879310"],"confidence":"High","gaps":["Whether ERG loss is causal in human pulmonary fibrosis not established","Specific ERG target genes mediating anti-fibrotic paracrine signaling not identified"]},{"year":2023,"claim":"CRISPR screens and ChIP-seq identified ERG as the critical downstream effector of EVI1 in AML, with EVI1 directly occupying an intragenic ERG enhancer, establishing a new oncogenic axis distinct from chromosomal fusions.","evidence":"CRISPR dependency screens; EVI1 ChIP-seq at ERG enhancer; ERG knockdown inducing differentiation; ERG rescue of EVI1-depleted AML cells","pmids":["36095844"],"confidence":"High","gaps":["Whether pharmacological ERG inhibition is feasible for EVI1-driven AML not tested","Full set of ERG target genes in AML context not mapped"]},{"year":null,"claim":"No direct small-molecule inhibitor or structural model of full-length ERG exists; the relative contributions of SPOP, TRIM25, and USP9X to ERG protein homeostasis across different tissues remain unquantified; and whether ERG's BAF-dependent chromatin remodeling mechanism operates in its endothelial and hematopoietic functions has not been tested.","evidence":"","pmids":[],"confidence":"High","gaps":["No crystal or cryo-EM structure of full-length ERG or ERG-BAF complex","Tissue-specific quantitative balance of ERG ubiquitin ligases and deubiquitinases undefined","Whether BAF dependence is a universal feature of ERG function across lineages untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,4,9,14,16,22,23,25,30,31,32]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[4,8,9,14,17,22,23,25,27,31,32,35]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,8,9,14,17,22,25,29,31,32]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[4,9,14,17,22,23,25,29,31,32,35]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[22,29,32]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[25,28]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[11,31]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,6,10,15,17,27,35]}],"complexes":["BAF/SWI-SNF chromatin remodeling complex"],"partners":["SPOP","TRIM25","USP9X","EP300","KDM4A","BRD4","FOXO1","JUN"],"other_free_text":[]},"mechanistic_narrative":"ERG is an ETS family transcription factor that functions as a master regulator of endothelial cell identity, hematopoietic stem cell differentiation, and tissue homeostasis, while acting as a potent oncogene when dysregulated. ERG binds ETS motifs genome-wide and recruits chromatin remodeling (BAF/SWI-SNF) and histone-modifying (p300, KDM4A) complexes to enhancers, directly activating target genes including VE-cadherin, DLL4, SOX9, CXCR4, PIM1, YAP1, EBF1, and PAX5; in endothelial cells, VEGF/ERK-mediated phosphorylation activates ERG to drive angiogenesis and capillary homeostasis, while in prostate epithelium, ERG redirects androgen receptor binding to non-canonical targets and silences basal lineage determinants such as Trp63 through three-dimensional chromatin remodeling [PMID:25, PMID:30078722, PMID:23426182, PMID:32701507, PMID:32541654]. ERG protein stability is controlled by SPOP/Cullin3-dependent ubiquitination targeting an N-terminal degron—lost in TMPRSS2-ERG fusion products—and by TRIM25-mediated ubiquitination counterbalanced by USP9X deubiquitination [PMID:26344095, PMID:26344096, PMID:27626314]. ERG is oncogenically activated through chromosomal fusions (TMPRSS2-ERG in prostate cancer, EWS-ERG and FUS-ERG in Ewing sarcoma), transcriptional upregulation by EVI1 in AML, and expression of a dominant-negative ERGalt isoform driven by DUX4 in B-ALL, and its overexpression is sufficient to transform fibroblasts and initiate prostate neoplasia in transgenic mice [PMID:7731694, PMID:18245377, PMID:8076344, PMID:36095844, PMID:27776115]."},"prefetch_data":{"uniprot":{"accession":"P11308","full_name":"Transcriptional regulator ERG","aliases":["Transforming protein ERG"],"length_aa":479,"mass_kda":53.8,"function":"Transcriptional regulator. May participate in transcriptional regulation through the recruitment of SETDB1 histone methyltransferase and subsequent modification of local chromatin structure","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P11308/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ERG","classification":"Not Classified","n_dependent_lines":11,"n_total_lines":1208,"dependency_fraction":0.009105960264900662},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ERG","total_profiled":1310},"omim":[{"mim_id":"621567","title":"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ibb; CDG1BB","url":"https://www.omim.org/entry/621567"},{"mim_id":"621558","title":"RETINAL DYSTROPHY, ZEITZ-HAN TYPE; RDZH","url":"https://www.omim.org/entry/621558"},{"mim_id":"621548","title":"RETINITIS PIGMENTOSA 101; RP101","url":"https://www.omim.org/entry/621548"},{"mim_id":"621543","title":"UBIQUITIN-ASSOCIATED PROTEIN 1-LIKE PROTEIN; UBAP1L","url":"https://www.omim.org/entry/621543"},{"mim_id":"621481","title":"MITOCHONDRIAL DNA DEPLETION SYNDROME 14A (ENCEPHALOMYOPATHIC TYPE); MTDPS14A","url":"https://www.omim.org/entry/621481"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":38.4}],"url":"https://www.proteinatlas.org/search/ERG"},"hgnc":{"alias_symbol":["erg-3","p55"],"prev_symbol":[]},"alphafold":{"accession":"P11308","domains":[{"cath_id":"1.10.150.50","chopping":"130-204","consensus_level":"high","plddt":83.7493,"start":130,"end":204},{"cath_id":"1.10.10.10","chopping":"291-398","consensus_level":"high","plddt":87.235,"start":291,"end":398}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P11308","model_url":"https://alphafold.ebi.ac.uk/files/AF-P11308-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P11308-F1-predicted_aligned_error_v6.png","plddt_mean":59.34},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ERG","jax_strain_url":"https://www.jax.org/strain/search?query=ERG"},"sequence":{"accession":"P11308","fasta_url":"https://rest.uniprot.org/uniprotkb/P11308.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P11308/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P11308"}},"corpus_meta":[{"pmid":"9551933","id":"PMC_9551933","title":"TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9551933","citation_count":565,"is_preprint":false},{"pmid":"27776115","id":"PMC_27776115","title":"Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.","date":"2016","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27776115","citation_count":248,"is_preprint":false},{"pmid":"18245377","id":"PMC_18245377","title":"A causal role for ERG in neoplastic transformation of prostate epithelium.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18245377","citation_count":236,"is_preprint":false},{"pmid":"23426182","id":"PMC_23426182","title":"ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.","date":"2013","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23426182","citation_count":228,"is_preprint":false},{"pmid":"18195090","id":"PMC_18195090","title":"Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18195090","citation_count":222,"is_preprint":false},{"pmid":"25915839","id":"PMC_25915839","title":"The oncogene ERG: a key factor in prostate cancer.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25915839","citation_count":211,"is_preprint":false},{"pmid":"10821442","id":"PMC_10821442","title":"Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain.","date":"2000","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/10821442","citation_count":206,"is_preprint":false},{"pmid":"7509828","id":"PMC_7509828","title":"Fas antigen and p55 TNF receptor signal apoptosis through distinct pathways.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7509828","citation_count":202,"is_preprint":false},{"pmid":"12907633","id":"PMC_12907633","title":"FUS/ERG gene fusions in Ewing's tumors.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12907633","citation_count":195,"is_preprint":false},{"pmid":"3476934","id":"PMC_3476934","title":"The erg gene: a human gene related to the ets oncogene.","date":"1987","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3476934","citation_count":188,"is_preprint":false},{"pmid":"26344095","id":"PMC_26344095","title":"SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/26344095","citation_count":178,"is_preprint":false},{"pmid":"21336263","id":"PMC_21336263","title":"ERG gene rearrangements are common in prostatic small cell carcinomas.","date":"2011","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/21336263","citation_count":167,"is_preprint":false},{"pmid":"9012748","id":"PMC_9012748","title":"Tissue and species distribution of mRNA for the IKr-like K+ channel, erg.","date":"1997","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/9012748","citation_count":150,"is_preprint":false},{"pmid":"10606630","id":"PMC_10606630","title":"Roles for tumor necrosis factor receptor p55 and sphingomyelinase in repairing the cutaneous permeability barrier.","date":"1999","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/10606630","citation_count":139,"is_preprint":false},{"pmid":"26344096","id":"PMC_26344096","title":"Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/26344096","citation_count":133,"is_preprint":false},{"pmid":"21677539","id":"PMC_21677539","title":"Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.","date":"2011","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21677539","citation_count":129,"is_preprint":false},{"pmid":"12388285","id":"PMC_12388285","title":"Functional and pharmacological properties of canine ERG potassium channels.","date":"2002","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12388285","citation_count":104,"is_preprint":false},{"pmid":"24505269","id":"PMC_24505269","title":"TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24505269","citation_count":100,"is_preprint":false},{"pmid":"16140924","id":"PMC_16140924","title":"The proto-oncogene ERG in megakaryoblastic leukemias.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16140924","citation_count":98,"is_preprint":false},{"pmid":"15625085","id":"PMC_15625085","title":"The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis.","date":"2004","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15625085","citation_count":98,"is_preprint":false},{"pmid":"22766791","id":"PMC_22766791","title":"Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma.","date":"2012","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/22766791","citation_count":97,"is_preprint":false},{"pmid":"19168790","id":"PMC_19168790","title":"ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19168790","citation_count":97,"is_preprint":false},{"pmid":"10623807","id":"PMC_10623807","title":"The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10623807","citation_count":95,"is_preprint":false},{"pmid":"8258524","id":"PMC_8258524","title":"The effects of dystrophin gene mutations on the ERG in mice and humans.","date":"1993","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/8258524","citation_count":92,"is_preprint":false},{"pmid":"30078722","id":"PMC_30078722","title":"Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.","date":"2018","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/30078722","citation_count":86,"is_preprint":false},{"pmid":"28849022","id":"PMC_28849022","title":"Significance of the TMPRSS2:ERG gene fusion in prostate cancer.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28849022","citation_count":84,"is_preprint":false},{"pmid":"8632902","id":"PMC_8632902","title":"Identification of anisomycin-activated kinases p45 and p55 in murine cells as MAPKAP kinase-2.","date":"1996","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8632902","citation_count":83,"is_preprint":false},{"pmid":"19250935","id":"PMC_19250935","title":"Retinal pathway origins of the pattern ERG of the mouse.","date":"2009","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/19250935","citation_count":82,"is_preprint":false},{"pmid":"19156837","id":"PMC_19156837","title":"Distinct genomic aberrations associated with ERG rearranged prostate cancer.","date":"2009","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19156837","citation_count":80,"is_preprint":false},{"pmid":"28536097","id":"PMC_28536097","title":"Dynamic regulation of VEGF-inducible genes by an ERK/ERG/p300 transcriptional network.","date":"2017","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/28536097","citation_count":75,"is_preprint":false},{"pmid":"18676740","id":"PMC_18676740","title":"Delineation of TMPRSS2-ERG splice variants in prostate cancer.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18676740","citation_count":73,"is_preprint":false},{"pmid":"21321361","id":"PMC_21321361","title":"Promotion and maintenance of leukemia by ERG.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21321361","citation_count":72,"is_preprint":false},{"pmid":"35879310","id":"PMC_35879310","title":"Dysfunctional ERG signaling drives pulmonary vascular aging and persistent fibrosis.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35879310","citation_count":71,"is_preprint":false},{"pmid":"9099731","id":"PMC_9099731","title":"Ligand-induced formation of p55 and p75 tumor necrosis factor receptor heterocomplexes on intact cells.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9099731","citation_count":69,"is_preprint":false},{"pmid":"9973400","id":"PMC_9973400","title":"TNF receptor p55 plays a pivotal role in murine keratinocyte apoptosis induced by ultraviolet B irradiation.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9973400","citation_count":68,"is_preprint":false},{"pmid":"26623558","id":"PMC_26623558","title":"Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26623558","citation_count":64,"is_preprint":false},{"pmid":"24762546","id":"PMC_24762546","title":"Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer.","date":"2014","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/24762546","citation_count":63,"is_preprint":false},{"pmid":"11834728","id":"PMC_11834728","title":"Regulation of an ERG K+ current by Src tyrosine kinase.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11834728","citation_count":63,"is_preprint":false},{"pmid":"15090257","id":"PMC_15090257","title":"Functions of erg K+ channels in excitable cells.","date":"2004","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15090257","citation_count":60,"is_preprint":false},{"pmid":"23480797","id":"PMC_23480797","title":"The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer.","date":"2013","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/23480797","citation_count":60,"is_preprint":false},{"pmid":"23611870","id":"PMC_23611870","title":"Tumor necrosis factor in traumatic brain injury: effects of genetic deletion of p55 or p75 receptor.","date":"2013","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23611870","citation_count":60,"is_preprint":false},{"pmid":"9620659","id":"PMC_9620659","title":"Distinct adapter proteins mediate acid versus neutral sphingomyelinase activation through the p55 receptor for tumor necrosis factor.","date":"1998","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/9620659","citation_count":60,"is_preprint":false},{"pmid":"8076344","id":"PMC_8076344","title":"ERG gene is translocated in an Ewing's sarcoma cell line.","date":"1994","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/8076344","citation_count":59,"is_preprint":false},{"pmid":"11499508","id":"PMC_11499508","title":"Tumor necrosis factor-alpha and its receptors, p55 and p75, in gingiva of adult periodontitis.","date":"2001","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/11499508","citation_count":58,"is_preprint":false},{"pmid":"16829577","id":"PMC_16829577","title":"Whirlin complexes with p55 at the stereocilia tip during hair cell development.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16829577","citation_count":57,"is_preprint":false},{"pmid":"20007548","id":"PMC_20007548","title":"Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20007548","citation_count":57,"is_preprint":false},{"pmid":"28986382","id":"PMC_28986382","title":"Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.","date":"2017","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28986382","citation_count":53,"is_preprint":false},{"pmid":"25263440","id":"PMC_25263440","title":"TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25263440","citation_count":52,"is_preprint":false},{"pmid":"9164935","id":"PMC_9164935","title":"TNF receptor p55 controls early acute graft-versus-host disease.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9164935","citation_count":52,"is_preprint":false},{"pmid":"22331093","id":"PMC_22331093","title":"Clinical potential of the ERG oncoprotein in prostate cancer.","date":"2012","source":"Nature reviews. Urology","url":"https://pubmed.ncbi.nlm.nih.gov/22331093","citation_count":51,"is_preprint":false},{"pmid":"7731694","id":"PMC_7731694","title":"Human ERG is a proto-oncogene with mitogenic and transforming activity.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7731694","citation_count":51,"is_preprint":false},{"pmid":"10455268","id":"PMC_10455268","title":"Separation of M-like current and ERG current in NG108-15 cells.","date":"1999","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10455268","citation_count":51,"is_preprint":false},{"pmid":"20636794","id":"PMC_20636794","title":"ERG rearrangement in small cell prostatic and lung cancer.","date":"2010","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/20636794","citation_count":49,"is_preprint":false},{"pmid":"22279422","id":"PMC_22279422","title":"Oncogenic activation of ERG: A predominant mechanism in prostate cancer.","date":"2011","source":"Journal of carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22279422","citation_count":48,"is_preprint":false},{"pmid":"27223260","id":"PMC_27223260","title":"BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27223260","citation_count":44,"is_preprint":false},{"pmid":"23535644","id":"PMC_23535644","title":"Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells.","date":"2013","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/23535644","citation_count":44,"is_preprint":false},{"pmid":"19151660","id":"PMC_19151660","title":"TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas.","date":"2009","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/19151660","citation_count":44,"is_preprint":false},{"pmid":"7535144","id":"PMC_7535144","title":"TNF-alpha, the great imitator: role of p55 and p75 TNF receptors in hematopoiesis.","date":"1994","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/7535144","citation_count":44,"is_preprint":false},{"pmid":"32541654","id":"PMC_32541654","title":"An Erg-driven transcriptional program controls B cell lymphopoiesis.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32541654","citation_count":42,"is_preprint":false},{"pmid":"20563261","id":"PMC_20563261","title":"Androgens Induce Functional CXCR4 through ERG Factor Expression in TMPRSS2-ERG Fusion-Positive Prostate Cancer Cells.","date":"2010","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20563261","citation_count":42,"is_preprint":false},{"pmid":"11278640","id":"PMC_11278640","title":"Identification of amino acid residues in the ETS transcription factor Erg that mediate Erg-Jun/Fos-DNA ternary complex formation.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278640","citation_count":42,"is_preprint":false},{"pmid":"32701507","id":"PMC_32701507","title":"ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming.","date":"2020","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/32701507","citation_count":41,"is_preprint":false},{"pmid":"33531470","id":"PMC_33531470","title":"Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33531470","citation_count":41,"is_preprint":false},{"pmid":"31749034","id":"PMC_31749034","title":"ISCEV extended protocol for the S-cone ERG.","date":"2019","source":"Documenta ophthalmologica. Advances in ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/31749034","citation_count":39,"is_preprint":false},{"pmid":"25378537","id":"PMC_25378537","title":"ERG expression in chondrogenic bone and soft tissue tumours.","date":"2014","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25378537","citation_count":38,"is_preprint":false},{"pmid":"23348902","id":"PMC_23348902","title":"Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.","date":"2013","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/23348902","citation_count":38,"is_preprint":false},{"pmid":"7880403","id":"PMC_7880403","title":"Expression of TNF-alpha and TNFR p55 in cultured amniochorion.","date":"1994","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/7880403","citation_count":38,"is_preprint":false},{"pmid":"23850495","id":"PMC_23850495","title":"Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.","date":"2013","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23850495","citation_count":37,"is_preprint":false},{"pmid":"12466946","id":"PMC_12466946","title":"Biophysical properties of heteromultimeric erg K+ channels.","date":"2002","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12466946","citation_count":36,"is_preprint":false},{"pmid":"28248553","id":"PMC_28248553","title":"Synergistic Role of Endothelial ERG and FLI1 in Mediating Pulmonary Vascular Homeostasis.","date":"2017","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28248553","citation_count":35,"is_preprint":false},{"pmid":"27109047","id":"PMC_27109047","title":"ETS transcription factor ERG cooperates with histone demethylase KDM4A.","date":"2016","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/27109047","citation_count":35,"is_preprint":false},{"pmid":"36095844","id":"PMC_36095844","title":"EVI1 drives leukemogenesis through aberrant ERG activation.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/36095844","citation_count":34,"is_preprint":false},{"pmid":"3948667","id":"PMC_3948667","title":"Pattern ERG and glaucomatous visual field defects.","date":"1986","source":"Documenta ophthalmologica. Advances in ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/3948667","citation_count":34,"is_preprint":false},{"pmid":"11312105","id":"PMC_11312105","title":"Selective expression of erg isoforms in human endothelial cells.","date":"2001","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11312105","citation_count":34,"is_preprint":false},{"pmid":"27626314","id":"PMC_27626314","title":"The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27626314","citation_count":34,"is_preprint":false},{"pmid":"25933120","id":"PMC_25933120","title":"Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25933120","citation_count":34,"is_preprint":false},{"pmid":"19897731","id":"PMC_19897731","title":"Erythrocyte scaffolding protein p55/MPP1 functions as an essential regulator of neutrophil polarity.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19897731","citation_count":33,"is_preprint":false},{"pmid":"29911685","id":"PMC_29911685","title":"Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers.","date":"2018","source":"European urology oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29911685","citation_count":32,"is_preprint":false},{"pmid":"26880803","id":"PMC_26880803","title":"Deletion of Interstitial Genes between TMPRSS2 and ERG Promotes Prostate Cancer Progression.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/26880803","citation_count":32,"is_preprint":false},{"pmid":"25639219","id":"PMC_25639219","title":"Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.","date":"2015","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25639219","citation_count":32,"is_preprint":false},{"pmid":"9570704","id":"PMC_9570704","title":"Function of p55 and its nonerythroid homologues.","date":"1998","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/9570704","citation_count":31,"is_preprint":false},{"pmid":"7558025","id":"PMC_7558025","title":"Genomic structure and nucleotide sequence of the p55 gene of the puffer fish Fugu rubripes.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7558025","citation_count":31,"is_preprint":false},{"pmid":"26097038","id":"PMC_26097038","title":"Articular cartilage endurance and resistance to osteoarthritic changes require transcription factor Erg.","date":"2015","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/26097038","citation_count":30,"is_preprint":false},{"pmid":"29202479","id":"PMC_29202479","title":"SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29202479","citation_count":28,"is_preprint":false},{"pmid":"15235086","id":"PMC_15235086","title":"Muscarinic modulation of erg potassium current.","date":"2004","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15235086","citation_count":27,"is_preprint":false},{"pmid":"22140532","id":"PMC_22140532","title":"ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22140532","citation_count":26,"is_preprint":false},{"pmid":"12868005","id":"PMC_12868005","title":"Impaired electroretinogram (ERG) response in apolipoprotein E-deficient mice.","date":"2003","source":"Current eye research","url":"https://pubmed.ncbi.nlm.nih.gov/12868005","citation_count":26,"is_preprint":false},{"pmid":"23472063","id":"PMC_23472063","title":"5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23472063","citation_count":25,"is_preprint":false},{"pmid":"15455796","id":"PMC_15455796","title":"A comparison of ERG abnormalities in XLRS and XLCSNB.","date":"2004","source":"Documenta ophthalmologica. Advances in ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/15455796","citation_count":25,"is_preprint":false},{"pmid":"23555854","id":"PMC_23555854","title":"ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23555854","citation_count":24,"is_preprint":false},{"pmid":"19027849","id":"PMC_19027849","title":"The role of the ETS factor erg in zebrafish vasculogenesis.","date":"2008","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/19027849","citation_count":24,"is_preprint":false},{"pmid":"26653555","id":"PMC_26653555","title":"Elevated expression of microRNA-30b in osteoarthritis and its role in ERG regulation of chondrocyte.","date":"2015","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/26653555","citation_count":23,"is_preprint":false},{"pmid":"30051493","id":"PMC_30051493","title":"Wnt receptor Frizzled 8 is a target of ERG in prostate cancer.","date":"2018","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/30051493","citation_count":22,"is_preprint":false},{"pmid":"25306899","id":"PMC_25306899","title":"Overexpression of ERG in cord blood progenitors promotes expansion and recapitulates molecular signatures of high ERG leukemias.","date":"2014","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/25306899","citation_count":22,"is_preprint":false},{"pmid":"11414766","id":"PMC_11414766","title":"Cloning and characterization of the human retina-specific gene MPP4, a novel member of the p55 subfamily of MAGUK proteins.","date":"2001","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/11414766","citation_count":22,"is_preprint":false},{"pmid":"24115221","id":"PMC_24115221","title":"Evaluation of ERG responsive proteome in prostate cancer.","date":"2013","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/24115221","citation_count":21,"is_preprint":false},{"pmid":"23380710","id":"PMC_23380710","title":"AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL.","date":"2013","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/23380710","citation_count":21,"is_preprint":false},{"pmid":"20814243","id":"PMC_20814243","title":"The oncogenic role of the ETS transcription factors MEF and ERG.","date":"2010","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/20814243","citation_count":20,"is_preprint":false},{"pmid":"23462600","id":"PMC_23462600","title":"Immunohistochemical evaluation of ERG expression in various benign and malignant tissues.","date":"2013","source":"Annals of clinical and laboratory science","url":"https://pubmed.ncbi.nlm.nih.gov/23462600","citation_count":20,"is_preprint":false},{"pmid":"22241697","id":"PMC_22241697","title":"The biological function of the WD40 repeat-containing protein p55/Caf1 in Drosophila.","date":"2012","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/22241697","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48647,"output_tokens":8060,"usd":0.13342},"stage2":{"model":"claude-opus-4-6","input_tokens":11839,"output_tokens":4202,"usd":0.246367},"total_usd":0.379787,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1987,\n      \"finding\": \"ERG was identified as a member of the ETS oncogene family, encoding a 363-residue protein with approximately 40% and 70% homology to two domains of v-ets oncogene, establishing its identity as a distinct ETS transcription factor.\",\n      \"method\": \"cDNA cloning and nucleotide sequence analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning and sequence characterization, foundational paper\",\n      \"pmids\": [\"3476934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ERG gene is translocated in Ewing's sarcoma via a chromosomal rearrangement juxtaposing the 5' end of EWS to the 3' end of ERG, generating an EWS/ERG fusion transcript expressed at elevated levels.\",\n      \"method\": \"RT-PCR, cytogenetic and molecular analysis of Ewing's sarcoma cell line\",\n      \"journal\": \"Cancer genetics and cytogenetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct sequencing and transcript detection of fusion gene in cancer cell line\",\n      \"pmids\": [\"8076344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Overexpression of ERG2 in NIH3T3 cells confers oncogenic transformation, including growth in low serum, colony formation in soft agar, and tumor formation in nude mice, establishing ERG as a proto-oncogene with mitogenic and transforming activity.\",\n      \"method\": \"Stable transfection of ERG2 expression construct into NIH3T3 cells; soft agar colony assay; nude mouse xenograft\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro and in vivo transformation assays with multiple orthogonal readouts\",\n      \"pmids\": [\"7731694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ERG isoforms (Erg-3/p55(Erg) and p38(Erg)) are selectively expressed in endothelial cells among human cell types, indicating isoform-specific roles in regulation of endothelial-restricted gene expression.\",\n      \"method\": \"RT-PCR, Northern blotting, 5'-RACE on primary and established human cell lines\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple molecular methods, single lab\",\n      \"pmids\": [\"11312105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ERG physically interacts with Jun/Fos heterodimer through its ETS DNA-binding domain; residue R367 is required for both DNA binding and Erg-Jun/Fos complex formation, while Y371 is specifically required for transcriptional synergy with Jun/Fos without abolishing DNA binding.\",\n      \"method\": \"Deletion and point mutagenesis of ERG ETS domain; in vitro binding and transcriptional activation assays; molecular modeling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution, mutagenesis, and functional assays in a single study\",\n      \"pmids\": [\"11278640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ERG1 K+ channel is constitutively tyrosine-phosphorylated and forms a signaling complex with Src tyrosine kinase; Src activation increases ERG current amplitude and shifts voltage dependence, while Src inhibition reduces ERG current.\",\n      \"method\": \"Co-immunoprecipitation; whole-cell patch clamp; Src-selective inhibitory/activating peptides; constitutively active v-Src transfection\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — co-IP plus electrophysiology plus mutagenesis/peptide tools, multiple methods\",\n      \"pmids\": [\"11834728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"In Ewing's tumors lacking EWS rearrangement, FUS is fused in-frame to ERG, placing the FUS transactivation domain adjacent to the ERG ETS DNA-binding domain, demonstrating interchangeability of TET family transactivation domains with ETS factors in oncogenesis.\",\n      \"method\": \"Sequence-level RT-PCR fusion transcript characterization; BAC FISH on metaphase and interphase nuclei\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct sequencing of fusion junctions plus FISH validation\",\n      \"pmids\": [\"12907633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Muscarinic receptor stimulation inhibits ERG1 K+ current through a Gq/11-dependent pathway requiring a minimum intracellular Ca2+ level but not a Ca2+ transient, protein kinase C, or tyrosine kinases; recovery is partially dependent on PIP2 resynthesis.\",\n      \"method\": \"Whole-cell patch clamp; co-expression with M1 muscarinic receptors; dominant-negative Gq; constitutively active G-protein constructs; BAPTA Ca2+ chelation; pharmacological inhibitors\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in defined expression system with multiple orthogonal pharmacological and molecular tools\",\n      \"pmids\": [\"15235086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ERG is expressed in hematopoietic stem cells and megakaryoblastic cells; forced ERG expression in K562 erythroleukemia cells induces an erythroid-to-megakaryoblastic phenotypic switch; ERG activates the gpIb megakaryocytic promoter and binds the gpIIb promoter and the SCL/TAL1 hematopoietic enhancer in vivo.\",\n      \"method\": \"Cell line forced expression; megakaryocytic differentiation assays; in vivo ChIP; promoter reporter assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP, promoter reporter, and functional differentiation assays in multiple cell systems\",\n      \"pmids\": [\"16140924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ERG is required for endothelial tube formation and cell survival; Erg inhibition reduces VE-cadherin expression; Erg binds directly to the VE-cadherin promoter (by ChIP) and transactivates it; overexpression of VE-cadherin partially rescues apoptosis caused by Erg inhibition; Erg knockdown in a Matrigel plug model decreases vascularization in vivo.\",\n      \"method\": \"Antisense oligonucleotides/siRNA knockdown; ChIP; transactivation assay; VE-cadherin-GFP rescue; in vivo Matrigel plug model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP + reporter assay + functional rescue + in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"18195090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Overexpression of ERG in luminal prostate epithelial cells is sufficient to initiate prostate neoplasia (focal PIN) in transgenic mice; ERG overexpression in prostate cell lines increases cell invasion, and ERG protein is expressed in neoplastic human prostate epithelium.\",\n      \"method\": \"Transgenic mouse model with luminal-targeted ERG expression; invasion assays in prostate cell lines; ERG protein detection by Western/IHC\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model plus in vitro invasion assays\",\n      \"pmids\": [\"18245377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In zebrafish, erg functions downstream of cloche, tal1/scl, and etsrp in the angioblast specification pathway, and plays a redundant but specific role in angioblast specification/proliferation and early angiogenesis, with synergistic interaction with etsrp.\",\n      \"method\": \"Zebrafish morpholino knockdown; gain-of-function injection; in situ hybridization; epistasis analysis with cloche and other pathway genes\",\n      \"journal\": \"Mechanisms of development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with multiple pathway components in vivo\",\n      \"pmids\": [\"19027849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome (Ts65Dn); functional reduction of Erg to disomy corrects megakaryocytosis and progenitor cell expansion, establishing Erg gene dosage as a key driver of myeloproliferative phenotypes.\",\n      \"method\": \"Loss-of-function allele introduced into trisomic mouse model; hematologic and histopathologic phenotyping\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function in disease-relevant in vivo model with clear phenotypic readout\",\n      \"pmids\": [\"20007548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ETS2, ERG, and FLI-1 overexpression promotes megakaryocyte expansion and, when combined with Gata1 mutations (knockdown or Gata1s knockin), immortalizes hematopoietic progenitors with JAK/STAT pathway activation.\",\n      \"method\": \"Retroviral overexpression in murine fetal liver progenitors; serial replating assays; flow cytometry; JAK/STAT pathway analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — defined genetic combinations with clear functional readouts (immortalization, differentiation block)\",\n      \"pmids\": [\"19168790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ERG transcription factor binds directly to the CXCR4 gene promoter and drives androgen-dependent CXCR4 expression in TMPRSS2-ERG fusion-positive prostate cancer cells; ERG knockdown abolishes androgen-induced CXCR4 upregulation and functional CXCR4 signaling.\",\n      \"method\": \"ChIP demonstrating ERG binding to CXCR4 promoter; siRNA-mediated ERG knockdown; androgen stimulation assays; CXCR4 functional assays\",\n      \"journal\": \"Translational oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP plus loss-of-function with functional downstream readout\",\n      \"pmids\": [\"20563261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Forced ERG expression in adult bone marrow cells alters differentiation and promotes T-ALL development (with acquisition of Notch1 mutations) and B cell precursor growth in mouse transplantation models; shRNA-mediated silencing of ERG attenuates growth of human leukemia cell lines, establishing ERG as required for leukemia maintenance.\",\n      \"method\": \"Mouse BM transplantation with ERG-overexpressing cells; shRNA knockdown in human leukemia lines; flow cytometric lineage analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model plus loss-of-function in human lines, multiple lineages tested\",\n      \"pmids\": [\"21321361\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ERG overexpression in prostate cells induces PIM1 upregulation; ERG directly binds the PIM1 promoter (by ChIP) in RWPE-1 prostate cells; PIM1 upregulation by ERG increases aneuploidy after taxane treatment and alters Cyclin B1 levels.\",\n      \"method\": \"ChIP of ERG at PIM1 promoter; siRNA-mediated ERG silencing; gene expression profiling; flow cytometry for aneuploidy\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus loss-of-function, single lab\",\n      \"pmids\": [\"22140532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ERG regulates SOX9 expression indirectly by opening a cryptic androgen receptor (AR)-regulated enhancer in the SOX9 gene; ERG redirects AR to non-canonical targets including SOX9, which is a critical downstream effector of ERG-mediated invasion and tumor growth in TMPRSS2-ERG fusion-positive prostate cancer.\",\n      \"method\": \"RNAi knockdown of ERG in VCaP cells; ChIP-seq for AR and ERG; invasion assays; SOX9 knockdown in vivo and in vitro\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP-seq + loss-of-function + in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"23426182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"miR-145 directly targets the 3' UTR of ERG mRNA; ectopic miR-145 expression reduces ERG protein levels in prostate cancer cells.\",\n      \"method\": \"3' UTR reporter assay; ectopic miR-145 expression with Western blot for ERG protein\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase reporter and protein reduction, single lab\",\n      \"pmids\": [\"23480797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ERG governs loss of DNA methylation at the TDRD1 promoter CpG island, leading to TDRD1 transcriptional activation; ERG dosage manipulation by siRNA and forced expression directly controls TDRD1 promoter methylation status in prostate cancer cells.\",\n      \"method\": \"MeDIP-seq; bisulfite sequencing; ERG siRNA knockdown and forced expression; DNMT inhibitor treatment\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide methylation profiling plus gain/loss of function, single lab\",\n      \"pmids\": [\"23555854\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SPOP, a Cullin 3-based E3 ubiquitin ligase substrate adaptor, promotes ubiquitination and proteasomal degradation of wild-type ERG by recognizing a degron motif at the ERG N-terminus; prostate cancer-associated SPOP mutants are deficient in ERG ubiquitination; CKI-mediated phosphorylation of ERG modulates SPOP-ERG interaction; DNA damage drugs (topoisomerase inhibitors) restore the SPOP/ΔERG interaction to promote ΔERG degradation.\",\n      \"method\": \"In vitro ubiquitination assay; co-immunoprecipitation; mutagenesis of ERG degron; proteasome inhibitor assays; pharmacological drug treatment\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro ubiquitination plus co-IP, mutagenesis, and pharmacological validation\",\n      \"pmids\": [\"26344095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"N-terminally truncated ERG proteins encoded by TMPRSS2-ERG fusions lack the N-terminal SPOP degron motif and are resistant to SPOP-mediated proteasomal degradation; prostate cancer-associated SPOP mutations also abrogate ERG degradation.\",\n      \"method\": \"In vitro ubiquitination assay; co-immunoprecipitation; degron mutagenesis; proteasomal degradation assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — independent replication of SPOP-ERG ubiquitination mechanism with degron mapping\",\n      \"pmids\": [\"26344096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ERG directly activates the YAP1 promoter through multiple ETS binding sites; ERG binds directly to KDM4A histone demethylase; ERG-KDM4A cooperation reduces H3K27me3 at the YAP1 promoter; YAP1 depletion phenocopies the growth-inhibitory effect of ERG depletion in VCaP prostate cancer cells.\",\n      \"method\": \"Co-IP; promoter reporter assay with ETS site mutagenesis; ChIP for H3K27me3; siRNA knockdown\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP plus ChIP plus reporter mutagenesis, single lab\",\n      \"pmids\": [\"27109047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ERG conditional knockout in mouse joints leads to progressive osteoarthritis-like cartilage degeneration; ERG directly binds ETS sites in the PTHrP and lubricin gene promoters to stimulate their expression; ERG is required for maintenance of articular cartilage homeostasis postnatally.\",\n      \"method\": \"Conditional knockout (Gdf5-Cre x floxed Erg); surgical OA model; promoter-reporter assays with mutated ETS binding sites; gene expression analysis\",\n      \"journal\": \"Arthritis & rheumatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with disease phenotype plus mechanistic reporter assays\",\n      \"pmids\": [\"26097038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TRIM25 E3 ubiquitin ligase binds and polyubiquitinates full-length and N-terminally truncated ERG variants in vitro; TRIM25 inactivation reduces ERG polyubiquitination and stabilizes ERG protein; ERG upregulates TRIM25 expression, creating a regulatory feedback loop; USP9X deubiquitinase counteracts TRIM25 to stabilize ERG.\",\n      \"method\": \"Co-immunoprecipitation; in vitro ubiquitination assay; TRIM25 knockdown with ERG stability measurement\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of ubiquitination plus co-IP and loss-of-function\",\n      \"pmids\": [\"27626314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"VEGF/ERK signaling induces phosphorylation and activation of ERG in endothelial cells; phospho-ERG recruits the co-activator p300 to drive transcription of DLL4 and a network of VEGF-responsive target genes; ERG ChIP-seq identifies conserved ERG-bound enhancer elements near these target genes including HLX.\",\n      \"method\": \"ERK inhibition; ERG phosphorylation assays; ChIP for ERG and p300; genome-wide gene expression; ChIP-seq; genome editing of ERG-bound HLX enhancer\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP-seq plus enhancer editing plus in vivo validation, multiple methods\",\n      \"pmids\": [\"28536097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The TMPRSS2-ERG encoded truncated ERG (ERGΔ39/T1-E4) binds to bromodomain-1 (BD1) of BRD4; ERG and BRD4 co-occupy a substantial portion of genomic sites; an acetylation-mimicking mutation in ERG enhances the ERG-BRD4 interaction and augments ERG-mediated cell invasion; BET inhibitors partially abrogate this interaction.\",\n      \"method\": \"Co-IP; ChIP-seq meta-analysis; acetylation-mimicking ERG mutant; BET inhibitor treatment; invasion assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP plus ChIP-seq overlap plus mutagenesis, single lab\",\n      \"pmids\": [\"27223260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"DUX4 rearrangement in B-ALL drives expression of a novel ERG isoform (ERGalt) via a non-canonical first exon initiated by DUX4 binding; ERGalt retains the DNA-binding and transactivation domains of ERG, functions as a dominant-negative inhibitor of wild-type ERG transcriptional activity, and is transforming.\",\n      \"method\": \"Genomic sequencing; transcriptional assays; dominant-negative functional assays; transformation assays\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — identification of DUX4 binding driving ERGalt expression plus functional dominant-negative and transformation assays\",\n      \"pmids\": [\"27776115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FOXO1 binds directly to ERG and inhibits its transcriptional activity independently of FOXO1's own transcriptional activity; FOXO1 knockdown increases invasion in TMPRSS2-ERG fusion-positive cells in an ERG-dependent manner; combined ERG transgene expression and Foxo1 deletion in mouse prostate produces high-grade PIN, whereas either alone does not.\",\n      \"method\": \"Co-IP of FOXO1 and ERG; FOXO1 knockdown + ERG knockdown epistasis; transgenic mouse model; in vitro invasion assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — co-IP plus epistatic genetic model plus in vitro functional assays\",\n      \"pmids\": [\"28986382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ERG interacts with the mammalian SWI/SNF (BAF) chromatin remodeling complex; ERG drives genome-wide retargeting of BAF complexes in an ETS DNA motif-dependent manner; ERG requires intact BAF complexes for chromatin occupancy and BAF ATPase activity for target gene regulation; BAF complexes are required for ERG-mediated basal-to-luminal transition in prostate organoids.\",\n      \"method\": \"Co-IP/pulldown; ChIP-seq of ERG and BAF subunits; BAF ATPase inhibition; prostate organoid model with BAF depletion\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — co-IP + genome-wide ChIP-seq + ATPase inhibition + organoid functional assay, multiple orthogonal methods\",\n      \"pmids\": [\"30078722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ERG directly binds and activates the FZD8 (Frizzled-8) gene promoter in prostate cancer cells; this activation is specific to ERG and not to the related ETS factor ETV1; ERG overexpression induces FZD8 expression, potentially activating Wnt signaling.\",\n      \"method\": \"ChIP demonstrating ERG binding at FZD8 promoter; promoter reporter assay; ERG knockdown; specificity comparison with ETV1\",\n      \"journal\": \"The Prostate\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus reporter assay, single lab\",\n      \"pmids\": [\"30051493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ERG is essential for early B lymphoid differentiation; ERG initiates a transcriptional network involving EBF1 and PAX5 that promotes expression of V(D)J recombination genes and B cell receptor formation; complementation of Erg deficiency with a rearranged immunoglobulin gene rescues B lineage development.\",\n      \"method\": \"Conditional Erg knockout; RNA-seq/ChIP-seq; rescue with productively rearranged Ig gene; flow cytometric developmental analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with genetic rescue plus genome-wide transcriptional network mapping\",\n      \"pmids\": [\"32541654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ERG inhibits a distal enhancer of Trp63 (a master regulator of prostate basal lineage) by binding it and reducing its chromatin looping activity, thereby silencing Trp63 and promoting luminal differentiation; specific deletion of the ERG-bound Trp63 enhancer removes ERG-mediated inhibition of basal differentiation.\",\n      \"method\": \"3D chromatin architecture analysis (Hi-C/ChIA-PET); ChIP-seq; ERG KO; AR KO comparison; targeted enhancer deletion\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — 3D chromatin mapping plus targeted enhancer editing plus genetic KOs\",\n      \"pmids\": [\"32701507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ERG upregulates wild-type SPOP to dampen androgen receptor (AR) signaling and sustains its own activity through SPOP-mediated degradation of the bromodomain histone reader ZMYND11; conversely, SPOP-mutant tumors stabilize ZMYND11 to repress ERG function, establishing opposing ERG-SPOP regulatory axes.\",\n      \"method\": \"Proteomics; ChIP-seq; co-IP; genetic manipulation of SPOP and ERG in organoid and mouse models; pharmacological SPOP inhibition\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including proteomics, ChIP-seq, genetic models\",\n      \"pmids\": [\"33531470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ERG functions as a transcriptional orchestrator of lung capillary homeostasis; loss of endothelial ERG enhances paracrine fibroblast activation in vitro and impairs lung fibrosis resolution in vivo; ERG-deficient mouse lungs show reduced general capillary (gCap) endothelial cell numbers and transcriptional abnormalities resembling aging and human lung fibrosis.\",\n      \"method\": \"Epigenetic/transcriptional analysis (ATAC-seq, RNA-seq); conditional ERG deletion; scRNA-seq; in vitro co-culture fibroblast activation assay; bleomycin lung fibrosis model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with in vivo fibrosis phenotype plus in vitro functional assays and scRNA-seq\",\n      \"pmids\": [\"35879310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"EVI1 oncogene directly activates ERG transcription by occupying a conserved intragenic ERG enhancer; ERG is selectively required for EVI1-driven AML; ectopic ERG expression rescues AML cell dependence on EVI1, establishing ERG as the major oncogenic effector downstream of EVI1.\",\n      \"method\": \"CRISPR screens; ChIP-seq for EVI1 at ERG enhancer; ERG knockdown causing terminal differentiation; ERG rescue of EVI1-depleted cells; in vivo mouse models\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — CRISPR screens + ChIP-seq + genetic rescue, orthogonal mechanistic evidence\",\n      \"pmids\": [\"36095844\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ERG is an ETS family transcription factor that binds DNA through its ETS domain and regulates target genes (including VE-cadherin, SOX9, CXCR4, PIM1, FZD8, YAP1, DLL4, PTHrP, EBF1, PAX5) directly or by redirecting cofactors such as AR, p300, KDM4A, and BAF chromatin remodeling complexes to enhancers; its protein stability is controlled by SPOP/Cullin3-mediated ubiquitination (dependent on an N-terminal degron) counterbalanced by USP9X deubiquitination, with TRIM25 as an additional E3 ligase; ERG is activated by VEGF/ERK-mediated phosphorylation in endothelial cells, modulated by Src tyrosine kinase and muscarinic/Gq signaling (in its role as the HERG K+ channel in cardiac/neuronal contexts), and is oncogenically activated in prostate cancer via TMPRSS2-ERG fusion (producing N-terminally truncated, SPOP-resistant isoforms), in leukemia via EWS/FUS fusions or EVI1-driven transcriptional upregulation, and in B-ALL via DUX4-driven expression of a dominant-negative ERGalt isoform.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ERG is an ETS family transcription factor that functions as a master regulator of endothelial cell identity, hematopoietic stem cell differentiation, and tissue homeostasis, while acting as a potent oncogene when dysregulated. ERG binds ETS motifs genome-wide and recruits chromatin remodeling (BAF/SWI-SNF) and histone-modifying (p300, KDM4A) complexes to enhancers, directly activating target genes including VE-cadherin, DLL4, SOX9, CXCR4, PIM1, YAP1, EBF1, and PAX5; in endothelial cells, VEGF/ERK-mediated phosphorylation activates ERG to drive angiogenesis and capillary homeostasis, while in prostate epithelium, ERG redirects androgen receptor binding to non-canonical targets and silences basal lineage determinants such as Trp63 through three-dimensional chromatin remodeling [PMID:25, PMID:30078722, PMID:23426182, PMID:32701507, PMID:32541654]. ERG protein stability is controlled by SPOP/Cullin3-dependent ubiquitination targeting an N-terminal degron—lost in TMPRSS2-ERG fusion products—and by TRIM25-mediated ubiquitination counterbalanced by USP9X deubiquitination [PMID:26344095, PMID:26344096, PMID:27626314]. ERG is oncogenically activated through chromosomal fusions (TMPRSS2-ERG in prostate cancer, EWS-ERG and FUS-ERG in Ewing sarcoma), transcriptional upregulation by EVI1 in AML, and expression of a dominant-negative ERGalt isoform driven by DUX4 in B-ALL, and its overexpression is sufficient to transform fibroblasts and initiate prostate neoplasia in transgenic mice [PMID:7731694, PMID:18245377, PMID:8076344, PMID:36095844, PMID:27776115].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"Establishing ERG as a distinct ETS family member resolved its identity as a transcription factor with conserved DNA-binding and pointed domains, providing the foundation for all subsequent functional studies.\",\n      \"evidence\": \"cDNA cloning and sequence analysis revealing a 363-residue protein with ETS domain homology\",\n      \"pmids\": [\"3476934\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No target genes identified\", \"No functional assay performed\", \"Expression pattern unknown\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Discovery of the EWS-ERG fusion in Ewing sarcoma established ERG as a recurrent translocation partner in human cancer, raising the question of whether ERG possesses intrinsic oncogenic activity.\",\n      \"evidence\": \"RT-PCR and cytogenetic analysis of Ewing sarcoma cell line identifying EWS-ERG fusion transcript\",\n      \"pmids\": [\"8076344\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transforming activity of the fusion not directly tested\", \"Mechanism of oncogenic activation unknown\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Demonstrating that ERG overexpression alone transforms NIH3T3 cells confirmed ERG as a bona fide proto-oncogene, establishing that its oncogenic potential does not require a fusion partner.\",\n      \"evidence\": \"Stable ERG2 transfection with soft agar colony formation and nude mouse tumor growth\",\n      \"pmids\": [\"7731694\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream transcriptional targets mediating transformation not identified\", \"Relevance to human epithelial cancers not shown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identification of endothelial-restricted ERG isoforms and mapping of the ETS domain's dual role in DNA binding and Jun/Fos interaction established ERG as a key endothelial transcription factor that integrates AP-1 signaling.\",\n      \"evidence\": \"RT-PCR/Northern blot profiling across human cell types; ETS domain mutagenesis with binding and transcriptional assays\",\n      \"pmids\": [\"11312105\", \"11278640\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endothelial target genes not identified\", \"In vivo endothelial requirement not tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showing that ERG drives megakaryocytic differentiation and directly occupies hematopoietic gene promoters (gpIb, gpIIb, SCL enhancer) revealed its role as a lineage-instructive transcription factor in hematopoiesis.\",\n      \"evidence\": \"Forced expression in K562 cells with differentiation assays; in vivo ChIP at megakaryocytic promoters\",\n      \"pmids\": [\"16140924\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Loss-of-function in hematopoietic stem cells not performed\", \"Functional redundancy with FLI-1 not resolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Multiple studies converged to establish ERG as essential for endothelial tube formation, VE-cadherin-mediated survival, angioblast specification, and—when overexpressed in prostate—sufficient to initiate neoplasia, revealing its dual physiological and oncogenic roles.\",\n      \"evidence\": \"siRNA knockdown with ChIP/rescue for VE-cadherin in HUVECs; zebrafish morpholino epistasis; transgenic ERG-overexpressing mouse prostate model with invasion assays\",\n      \"pmids\": [\"18195090\", \"19027849\", \"18245377\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endothelial ERG target gene network not mapped genome-wide\", \"Cooperating oncogenic events for prostate cancer progression not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Genetic dosage experiments in trisomic mice demonstrated that Erg trisomy is required for myeloproliferation in Down syndrome, establishing ERG gene dosage as a driver of megakaryocyte expansion and linking it to human disease.\",\n      \"evidence\": \"Reduction of Erg to disomy in Ts65Dn mice correcting megakaryocytosis and progenitor expansion\",\n      \"pmids\": [\"20007548\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets mediating megakaryocyte expansion not identified\", \"Cooperation with GATA1 mutations in transient myeloproliferative disease not fully dissected\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"ChIP-seq in TMPRSS2-ERG fusion-positive prostate cancer cells revealed that ERG redirects androgen receptor to non-canonical enhancers including a cryptic SOX9 enhancer, establishing the mechanistic basis for ERG's oncogenic transcriptional reprogramming.\",\n      \"evidence\": \"Integrated ERG/AR ChIP-seq in VCaP cells; SOX9 knockdown phenocopying ERG loss in invasion and tumor growth\",\n      \"pmids\": [\"23426182\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ERG-AR interaction unknown\", \"Whether AR redirection is sufficient without additional cofactors not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Two independent groups simultaneously discovered that SPOP/Cullin3 ubiquitinates ERG via an N-terminal degron that is absent in TMPRSS2-ERG fusion products, explaining why fusion-derived ERG escapes proteasomal degradation in prostate cancer.\",\n      \"evidence\": \"In vitro ubiquitination reconstitution; degron mutagenesis; proteasomal degradation assays with SPOP wild-type and cancer mutants\",\n      \"pmids\": [\"26344095\", \"26344096\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo therapeutic restoration of ERG degradation not demonstrated\", \"Quantitative contribution of SPOP versus TRIM25 pathways unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Conditional ERG knockout in mouse joints revealed a physiological requirement for ERG in articular cartilage homeostasis through direct transcriptional activation of PTHrP and lubricin, extending ERG's known roles beyond endothelium and blood.\",\n      \"evidence\": \"Gdf5-Cre conditional knockout with progressive osteoarthritis phenotype; promoter-reporter assays with ETS site mutations\",\n      \"pmids\": [\"26097038\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ERG loss contributes to human osteoarthritis not established\", \"Upstream signals regulating ERG in chondrocytes unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identification of TRIM25 as an additional E3 ligase for ERG and USP9X as a counteracting deubiquitinase, together with the discovery that ERG upregulates TRIM25 to create a feedback loop, revealed a multi-layered ubiquitin-dependent control circuit governing ERG protein levels.\",\n      \"evidence\": \"In vitro ubiquitination with TRIM25; co-IP of USP9X-ERG; TRIM25 knockdown stabilizing ERG protein\",\n      \"pmids\": [\"27626314\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative quantitative contribution of TRIM25 versus SPOP in different cell types not determined\", \"Structural basis of USP9X recognition of ERG unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"VEGF/ERK-dependent phosphorylation of ERG was shown to recruit p300 to drive DLL4 and angiogenic target gene transcription, while DUX4-driven ERGalt in B-ALL was identified as a dominant-negative isoform, demonstrating how post-translational and isoform-level mechanisms diversify ERG function.\",\n      \"evidence\": \"ERK inhibition with ERG phosphorylation and p300 ChIP assays; ChIP-seq enhancer mapping in endothelial cells; genomic sequencing and functional assays for DUX4-driven ERGalt\",\n      \"pmids\": [\"28536097\", \"27776115\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of kinase(s) phosphorylating specific ERG residues in endothelial cells not fully mapped\", \"Structural basis of ERGalt dominant-negative activity not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstration that ERG physically recruits and retargets BAF chromatin remodeling complexes genome-wide, and that BAF ATPase activity is required for ERG's transcriptional output, established BAF as the principal chromatin effector of ERG-driven gene regulation.\",\n      \"evidence\": \"Co-IP/pulldown; genome-wide ChIP-seq of ERG and BAF subunits; BAF ATPase inhibition; prostate organoid basal-to-luminal transition assay\",\n      \"pmids\": [\"30078722\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether specific BAF subunit composition dictates ERG-dependent enhancer selection unknown\", \"Whether BAF dependence applies to ERG functions in endothelial cells not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"ERG was shown to be essential for early B lymphopoiesis by initiating a transcription factor cascade (EBF1, PAX5) required for V(D)J recombination, and separately to silence the basal lineage determinant Trp63 through three-dimensional chromatin loop disruption, revealing ERG as a master regulator of lineage fate in multiple tissues.\",\n      \"evidence\": \"Conditional Erg KO with RNA-seq/ChIP-seq and Ig gene rescue in B cells; Hi-C/ChIA-PET plus targeted enhancer deletion for Trp63 in prostate\",\n      \"pmids\": [\"32541654\", \"32701507\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ERG's 3D chromatin remodeling role extends to hematopoietic loci not examined\", \"Redundancy with other ETS factors in B cell development not fully resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Conditional endothelial ERG deletion in adult mouse lungs impaired capillary homeostasis and fibrosis resolution, with transcriptional signatures resembling human lung fibrosis and aging, extending ERG's essential endothelial role from development to adult tissue maintenance.\",\n      \"evidence\": \"Conditional ERG deletion; scRNA-seq showing gCap loss; ATAC-seq/RNA-seq; bleomycin fibrosis model; in vitro paracrine fibroblast activation assay\",\n      \"pmids\": [\"35879310\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ERG loss is causal in human pulmonary fibrosis not established\", \"Specific ERG target genes mediating anti-fibrotic paracrine signaling not identified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"CRISPR screens and ChIP-seq identified ERG as the critical downstream effector of EVI1 in AML, with EVI1 directly occupying an intragenic ERG enhancer, establishing a new oncogenic axis distinct from chromosomal fusions.\",\n      \"evidence\": \"CRISPR dependency screens; EVI1 ChIP-seq at ERG enhancer; ERG knockdown inducing differentiation; ERG rescue of EVI1-depleted AML cells\",\n      \"pmids\": [\"36095844\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether pharmacological ERG inhibition is feasible for EVI1-driven AML not tested\", \"Full set of ERG target genes in AML context not mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"No direct small-molecule inhibitor or structural model of full-length ERG exists; the relative contributions of SPOP, TRIM25, and USP9X to ERG protein homeostasis across different tissues remain unquantified; and whether ERG's BAF-dependent chromatin remodeling mechanism operates in its endothelial and hematopoietic functions has not been tested.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal or cryo-EM structure of full-length ERG or ERG-BAF complex\", \"Tissue-specific quantitative balance of ERG ubiquitin ligases and deubiquitinases undefined\", \"Whether BAF dependence is a universal feature of ERG function across lineages untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 4, 9, 14, 16, 22, 23, 25, 30, 31, 32]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [4, 8, 9, 14, 17, 22, 23, 25, 27, 31, 32, 35]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 8, 9, 14, 17, 22, 25, 29, 31, 32]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4, 9, 14, 17, 22, 23, 25, 29, 31, 32, 35]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [22, 29, 32]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [25, 28]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [11, 31]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 6, 10, 15, 17, 27, 35]}\n    ],\n    \"complexes\": [\n      \"BAF/SWI-SNF chromatin remodeling complex\"\n    ],\n    \"partners\": [\n      \"SPOP\",\n      \"TRIM25\",\n      \"USP9X\",\n      \"EP300\",\n      \"KDM4A\",\n      \"BRD4\",\n      \"FOXO1\",\n      \"JUN\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}